A. Raimondi, M. Prisciandaro, F. Pagani, G. Randon, F. Corti, F. Nichetti, M. Niger, F. Morano, F. Pietrantonio, M. Di Bartolomeo
{"title":"THE EMERGING ROLE OF IMMUNOTHERAPY IN GASTROESOPHAGEAL CANCER: STATE OF ART AND FUTURE PERSPECTIVE","authors":"A. Raimondi, M. Prisciandaro, F. Pagani, G. Randon, F. Corti, F. Nichetti, M. Niger, F. Morano, F. Pietrantonio, M. Di Bartolomeo","doi":"10.48286/aro.2022.34","DOIUrl":"https://doi.org/10.48286/aro.2022.34","url":null,"abstract":"","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117252867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CAR T CELL THERAPY. A NEW MILESTONE IN THE TREATMENT OF B CELL LYMPHOMAS","authors":"M. Nizzoli, A. Bavieri, S. Luminari","doi":"10.48286/aro.2022.35","DOIUrl":"https://doi.org/10.48286/aro.2022.35","url":null,"abstract":"","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122381626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Lombardi, R. Falcone, M. Filetti, V. Altamura, R. Giusti, F. Paroni Sterbini, A. Pietragalla, S. Duranti, G. Scambia, G. Daniele
{"title":"ACCESS TO EARLY PHASE CLINICAL TRIALS AT THE TIME OF THE COVID-19 PANDEMIC: AN ITALIAN SURVEY","authors":"P. Lombardi, R. Falcone, M. Filetti, V. Altamura, R. Giusti, F. Paroni Sterbini, A. Pietragalla, S. Duranti, G. Scambia, G. Daniele","doi":"10.48286/aro.2022.38","DOIUrl":"https://doi.org/10.48286/aro.2022.38","url":null,"abstract":"","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"98 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116261312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"TACKLING CANCER AS WE DID WITH COVID19: A GLOBAL CHALLENGE THAT NEEDS A COOPERATIVE EFFORT","authors":"A. Giordano","doi":"10.48286/aro.2022.37","DOIUrl":"https://doi.org/10.48286/aro.2022.37","url":null,"abstract":"","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125177392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Di Fiore, A. Agius, C. Camenzuli, S. Suleiman, J. Calleja Agius, C. Savona Ventura
{"title":"GONADOBLASTOMA: A BRIEF REPORT","authors":"R. Di Fiore, A. Agius, C. Camenzuli, S. Suleiman, J. Calleja Agius, C. Savona Ventura","doi":"10.48286/aro.2022.36","DOIUrl":"https://doi.org/10.48286/aro.2022.36","url":null,"abstract":"","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116235753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Gussoni, E. Ravot, M. Zecchina, G. Recchia, E. Santoro, R. Ascione, F. Perrone
Digital therapeutics (DTx) have been defined as technologies that “offer therapeutic interventions driven by high-quality software programs, based on scientific evidence obtained through methodologically rigorous confirmatory clinical investigation, to prevent, manage and treat a broad spectrum of physical, mental and behavioural conditions”. DTx products are on the market in a number of countries or under development for a broad range of physical and behavioral conditions, including oncology treatment management. The aim of this narrative review is to provide an update on findings available for DTx, specifically developed for the treatment of patients with cancer. A search was conducted using the following databases: PubMed, Google Scholar, Clinicaltrials.gov and Deutsches Register
数字疗法(DTx)被定义为“提供由高质量软件程序驱动的治疗干预措施，基于通过方法学上严格的验证性临床调查获得的科学证据，以预防、管理和治疗广泛的身体、精神和行为状况”的技术。DTx产品已在许多国家上市或正在开发中，用于广泛的身体和行为状况，包括肿瘤治疗管理。这篇叙述性综述的目的是提供DTx的最新研究结果，专门用于治疗癌症患者。使用以下数据库进行搜索:PubMed, Google Scholar, Clinicaltrials.gov和Deutsches Register
{"title":"DIGITAL THERAPEUTICS IN ONCOLOGY: FINDINGS, BARRIERS AND PROSPECTS. A NARRATIVE REVIEW","authors":"G. Gussoni, E. Ravot, M. Zecchina, G. Recchia, E. Santoro, R. Ascione, F. Perrone","doi":"10.48286/aro.2022.39","DOIUrl":"https://doi.org/10.48286/aro.2022.39","url":null,"abstract":"Digital therapeutics (DTx) have been defined as technologies that “offer therapeutic interventions driven by high-quality software programs, based on scientific evidence obtained through methodologically rigorous confirmatory clinical investigation, to prevent, manage and treat a broad spectrum of physical, mental and behavioural conditions”. DTx products are on the market in a number of countries or under development for a broad range of physical and behavioral conditions, including oncology treatment management. The aim of this narrative review is to provide an update on findings available for DTx, specifically developed for the treatment of patients with cancer. A search was conducted using the following databases: PubMed, Google Scholar, Clinicaltrials.gov and Deutsches Register","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"80 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128644231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Mangone, I. Bisceglia, C. Sacchettini, P. Mancuso, G. Carlinfante, P. Giorgi Rossi, A. AIRTUM Working Group
Neuroendocrine neoplasms (NENs) account for 0.5% of all neoplasms worldwide. The aim of the study was to describe the epidemiology of NENs in Italy and the association with a second neoplasm using the Italian Cancer Registries (AIRTUM) database. Thirty-eight cancer registries were involved in this study in the period 1976-2012. The standardized incidence rates and the relative 5-year survival are reported. Cases by site, sex, and age, and the second cancers associated with patients with NENs are described. A total of 9,707 NENs were reported to the AIRTUM database: 5,318 males (54.8%) and 4,389 females (45.2%). Lung and small intestine were the most frequent sites in both sexes. The standardized incidence increased from 1 case per 100,000/year (1976) to 5.46 case per 100,000/year in 2010 (95% CI 4.90-6.06), with a significant difference between 1 Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy 2 Department of Medical Sciences, University of Turin, Turin, Italy 3 Pathology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy 4 Associazione Italiana Registri Tumori (AIRTUM), Italy CORRESPONDING AUTHOR: Lucia Mangone Epidemiology Unit AUSL–IRCCS di Reggio Emilia via Amendola 2 42122 Reggio Emilia, Italy E-mail: mangone.lucia@ausl.re.it ORCID: 0000-0003-4850-2678 Doi: 10.48286/aro.2021.14 History Received: Mar 25, 2021 Accepted: Apr 6, 2021 Published: Jun 1, 2021 L. Mangone 1, I. Bisceglia 1, C. Sacchettini 2, P. Mancuso 1, G. Carlinfante 3, P. Giorgi Rossi 1, AIRTUM Working Group 4 NEUROENDOCRINE NEOPLASMS IN ITALY rates in males (6.51, 95% CI 5.61-7.51) and in females (4.60, 95 CI 3.91-5.37). Incidence increased gradually in both sexes up to age 40-45, after which it increased rapidly. The 5-year relative survival was 59.7% (53.9% in males and 66.5% in females). NEN patients had a slight, not significant excess risk of having a second tumour: standardized incidence ratio 1.06 (95% CI 0.98-1.15). Of the 9,707 NENs studied, 2,033 (21%) had a second neoplasm: among these, 29 were NENs, 1,360 were other previous tumours, and 644 were other following tumours (78 synchronous and 566 metachronous tumours). Although traditionally thought to be rare, incidence has increased by nearly sevenfold since 1976. Differences in registration accuracy and classification criteria challenge comparisons between areas and time. Annals of Research in Oncology Vol. 1(2), 119-129, 2021
神经内分泌肿瘤(NENs)占全球所有肿瘤的0.5%。该研究的目的是利用意大利癌症登记处(AIRTUM)数据库描述意大利NENs的流行病学及其与第二种肿瘤的关系。在1976年至2012年期间，38个癌症登记处参与了这项研究。报告标准化发病率和相对5年生存率。按部位、性别和年龄分类的病例以及与NENs患者相关的第二种癌症进行了描述。AIRTUM数据库共报告了9707例NENs，其中男性5318例(54.8%)，女性4389例(45.2%)。肺和小肠是两性中最常见的部位。标准化发病率从1976年的1例/ 10万/年增加到2010年的5.46例/ 10万/年(95% CI 4.90-6.06)，其中1个流行病学单位，意大利雷焦艾米利亚地区联合医院- irccs，意大利雷焦艾米利亚，意大利都灵大学医学系，意大利都灵3个病理单位，意大利雷焦艾米利亚地区联合医院- irccs，意大利雷焦艾米利亚，意大利雷焦艾米利亚，4意大利肿瘤登记协会(AIRTUM)，通讯作者:Lucia Mangone流行病学单位AUSL-IRCCS di Reggio Emilia via Amendola 2 42122 Reggio Emilia, Italy E-mail: mangone.lucia@ausl.re.it ORCID: 0000-0003-4850-2678 Doi: 10.48286/aro.2021.14接收时间:2021年3月25日接收时间:2021年4月6日发布时间:L. Mangone 1, I. Bisceglia 1, C. Sacchettini 2, P. Mancuso 1, G. Carlinfante 3, P. Giorgi Rossi 1, AIRTUM工作组4意大利神经内分泌肿瘤发病率男性(6.51,95% CI 5.61-7.51)，女性(4.60,95% CI 3.91-5.37)。在40-45岁之前，男女发病率逐渐增加，之后迅速增加。5年相对生存率为59.7%(男性53.9%，女性66.5%)。NEN患者有轻微但不显著的第二肿瘤额外风险:标准化发病率比1.06 (95% CI 0.98-1.15)。在研究的9,707例nen中，2,033例(21%)患有第二肿瘤:其中29例为nen, 1,360例为其他既往肿瘤，644例为其他后续肿瘤(78例为同步肿瘤，566例为异时肿瘤)。虽然传统上认为罕见，但自1976年以来发病率增加了近7倍。注册精度和分类标准的差异对区域和时间之间的比较提出了挑战。中国肿瘤学杂志Vol. 1(2)， 119-129, 2021
{"title":"NEUROENDOCRINE NEOPLASMS IN ITALY","authors":"L. Mangone, I. Bisceglia, C. Sacchettini, P. Mancuso, G. Carlinfante, P. Giorgi Rossi, A. AIRTUM Working Group","doi":"10.48286/aro.2021.14","DOIUrl":"https://doi.org/10.48286/aro.2021.14","url":null,"abstract":"Neuroendocrine neoplasms (NENs) account for 0.5% of all neoplasms worldwide. The aim of the study was to describe the epidemiology of NENs in Italy and the association with a second neoplasm using the Italian Cancer Registries (AIRTUM) database. Thirty-eight cancer registries were involved in this study in the period 1976-2012. The standardized incidence rates and the relative 5-year survival are reported. Cases by site, sex, and age, and the second cancers associated with patients with NENs are described. A total of 9,707 NENs were reported to the AIRTUM database: 5,318 males (54.8%) and 4,389 females (45.2%). Lung and small intestine were the most frequent sites in both sexes. The standardized incidence increased from 1 case per 100,000/year (1976) to 5.46 case per 100,000/year in 2010 (95% CI 4.90-6.06), with a significant difference between 1 Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy 2 Department of Medical Sciences, University of Turin, Turin, Italy 3 Pathology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy 4 Associazione Italiana Registri Tumori (AIRTUM), Italy CORRESPONDING AUTHOR: Lucia Mangone Epidemiology Unit AUSL–IRCCS di Reggio Emilia via Amendola 2 42122 Reggio Emilia, Italy E-mail: mangone.lucia@ausl.re.it ORCID: 0000-0003-4850-2678 Doi: 10.48286/aro.2021.14 History Received: Mar 25, 2021 Accepted: Apr 6, 2021 Published: Jun 1, 2021 L. Mangone 1, I. Bisceglia 1, C. Sacchettini 2, P. Mancuso 1, G. Carlinfante 3, P. Giorgi Rossi 1, AIRTUM Working Group 4 NEUROENDOCRINE NEOPLASMS IN ITALY rates in males (6.51, 95% CI 5.61-7.51) and in females (4.60, 95 CI 3.91-5.37). Incidence increased gradually in both sexes up to age 40-45, after which it increased rapidly. The 5-year relative survival was 59.7% (53.9% in males and 66.5% in females). NEN patients had a slight, not significant excess risk of having a second tumour: standardized incidence ratio 1.06 (95% CI 0.98-1.15). Of the 9,707 NENs studied, 2,033 (21%) had a second neoplasm: among these, 29 were NENs, 1,360 were other previous tumours, and 644 were other following tumours (78 synchronous and 566 metachronous tumours). Although traditionally thought to be rare, incidence has increased by nearly sevenfold since 1976. Differences in registration accuracy and classification criteria challenge comparisons between areas and time. Annals of Research in Oncology Vol. 1(2), 119-129, 2021","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125080302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"SARS-CoV-2 and oncology","authors":"L. Fratino, D. Serraino","doi":"10.48286/aro.2021.12","DOIUrl":"https://doi.org/10.48286/aro.2021.12","url":null,"abstract":"","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132092028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Lai, A. Satta, G. Pinna, L.M. Altana, G. Senes, P. Coni, G. Faa
Thyroid cancer is considered uncommon in pediatrics, yet it is the most common endocrine malignancy among them. The aim of this study was to analyze pediatric thyroid carcinomas diagnosed in Sardinian children and adolescents in order to find a possible association with autoimmune diseases. We studied 63 consecutive 10-20-years-old patients who underwent surgery for thyroid cancer between January 2001 and April 2020 in our hospital. No evidence of risk factors including external radiation was found. All cases were follicular-derived neoplasms: 45 PTCs (72%), 9 FTCs (14%), 2 well differentiated carcinomas not otherwise specified (3%), 2 poorly differentiated carcinomas (3%), 5 cases of encapsulated PTC-FV were re-diagnosed as NIFTP
{"title":"Thyroid cancer in Sardinian pediatric patients: report of 63 cases and a review of the literature","authors":"M. Lai, A. Satta, G. Pinna, L.M. Altana, G. Senes, P. Coni, G. Faa","doi":"10.48286/aro.2021.32","DOIUrl":"https://doi.org/10.48286/aro.2021.32","url":null,"abstract":"Thyroid cancer is considered uncommon in pediatrics, yet it is the most common endocrine malignancy among them. The aim of this study was to analyze pediatric thyroid carcinomas diagnosed in Sardinian children and adolescents in order to find a possible association with autoimmune diseases. We studied 63 consecutive 10-20-years-old patients who underwent surgery for thyroid cancer between January 2001 and April 2020 in our hospital. No evidence of risk factors including external radiation was found. All cases were follicular-derived neoplasms: 45 PTCs (72%), 9 FTCs (14%), 2 well differentiated carcinomas not otherwise specified (3%), 2 poorly differentiated carcinomas (3%), 5 cases of encapsulated PTC-FV were re-diagnosed as NIFTP","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"102 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117295428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Gerosa, D. Fanni, E. Massa, E. Lai, A. Ravarino, M. Debiec-Richter, G. Faa, M. Scartozzi, R. Sciot
Soft tissue epithelioid vascular tumors are characterized by a wide spectrum and represent a controversial topic for overlapping morphologic features; they require depth knowledge of the various subtypes, in order to be able to predict the clinical behaviour of the lesion. The World Health Organization (WHO) classification of soft tissue tumours recognizes multiple vascular tumours with epithelioid features, with different levels of malignancy: 1) benign neoplasms, as epithelioid hemangioma (EH) 2) tumours with an intermediate behaviour, characterized by low distant metastatic rates, including pseudomyogenic hemangioendothelioma (PHE); 3) malignant vascular tumours, with higher metastatic rate, as epithelioid hemangioendothelioma (EHE) and the epithelioid variant of angiosarcoma (EAS). The aim of this review is to report the most important clinical, pathological, immuhistochemical and cytogenetic features of epithelioid vascular tumours. In order to reach the correct diagnosis, the identification of epithelioid features, immunohistochemical (CD31 and ERG) and cytogenetic (CAMPTA1 and FLI1) markers are able to make more reproducible the interpretation of this complex group of soft tissue neoplasms.
{"title":"SOFT TISSUE EPITHELIOID VASCULAR TUMORS: A PRACTICAL CLINICO PATHOLOGICAL DIAGNOSTIC APPROACH","authors":"C. Gerosa, D. Fanni, E. Massa, E. Lai, A. Ravarino, M. Debiec-Richter, G. Faa, M. Scartozzi, R. Sciot","doi":"10.48286/aro.2021.26","DOIUrl":"https://doi.org/10.48286/aro.2021.26","url":null,"abstract":"Soft tissue epithelioid vascular tumors are characterized by a wide spectrum and represent a controversial topic for overlapping morphologic features; they require depth knowledge of the various subtypes, in order to be able to predict the clinical behaviour of the lesion. The World Health Organization (WHO) classification of soft tissue tumours recognizes multiple vascular tumours with epithelioid features, with different levels of malignancy: 1) benign neoplasms, as epithelioid hemangioma (EH) 2) tumours with an intermediate behaviour, characterized by low distant metastatic rates, including pseudomyogenic hemangioendothelioma (PHE); 3) malignant vascular tumours, with higher metastatic rate, as epithelioid hemangioendothelioma (EHE) and the epithelioid variant of angiosarcoma (EAS). The aim of this review is to report the most important clinical, pathological, immuhistochemical and cytogenetic features of epithelioid vascular tumours. In order to reach the correct diagnosis, the identification of epithelioid features, immunohistochemical (CD31 and ERG) and cytogenetic (CAMPTA1 and FLI1) markers are able to make more reproducible the interpretation of this complex group of soft tissue neoplasms.","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127823996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：